Peripheral Subcutaneous Field Stimulation (PSFS)
Customize your policy alerts
Sign up for Capital Bluecross Policy MP 1.141 alerts
Get alerted when Policy MP 1.141 changes without checking for updates manually.
Monitor payer policy activity
Governs Capital Bluecross coverage stance for peripheral subcutaneous field stimulation (PSFS) for chronic neuropathic and other chronic pain indications; applies to products and programs administered by Capital Blue Cross with benefit variations noted.
No material clinical or coverage changes in this revision.
Coverage Criteria and Policy Stance
Coverage decision
Capital Bluecross considers peripheral subcutaneous field stimulation investigational and not covered due to insufficient evidence of improvement in net health outcome.
Coverage statement and policy history
Administrative and policy status summary for this policy.
Capital Bluecross considers peripheral subcutaneous field stimulation (PSFS) investigational and not covered. The evidence is insufficient to support a general conclusion that PSFS improves net health outcomes for chronic neuropathic or other chronic pain indications; larger, prospective controlled trials comparing PSFS with placebo or alternative treatments are needed to determine efficacy. (See rationale and summary of evidence describing randomized trials, comparative studies, and case series.)
Permanent implantation of PSFS is typically preceded by a trial of percutaneous stimulation with at least 50% pain reduction, but even with this trial paradigm the current literature (including randomized and pilot trials and multiple case series) does not provide adequate demonstration of clinically meaningful benefit or consistent outcome improvement.
This policy applies only to certain programs and products administered by Capital Blue Cross and is subject to benefit variations; final coverage and payment determination is based on the member's benefit program, eligibility on the date of service, and medical necessity determinations. Providers should refer to member benefit information and product-specific variances (including FEP guidance) for applicability.
Procedure coding identified in this policy that is considered investigational and therefore not covered includes CPT 64999 (unlisted procedure, nervous system). Coding and administrative history show multiple consensus reviews with no change to the policy statement and no coding changes recorded during the listed reviews; an administrative update on 07/23/2025 removed the Benefit Variations section and updated the Disclaimer.
Coding and Billing
| 64999 | Unlisted procedure, nervous system (investigational usage flagged) |
| No codes listed |
Provider Actions, Eligibility, and Administrative Notes
Verify program/product applicability and member benefits before treatment
This policy applies only to certain programs and products administered by Capital Blue Cross and is subject to benefit variations; verify member benefits and program applicability prior to providing services. For Federal Employee Program (FEP) PPO members, refer to the FEP Medical Policy Manual for applicable coverage rules.
- Confirm the member's benefit program and product administered by Capital Blue Cross before scheduling or billing services.
- For FEP PPO members, consult the FEP Medical Policy Manual at https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-managementguidelines/medical-policies.
Coverage and payment subject to member benefit, eligibility, and medical necessity
Payment and coverage for services described in this policy are determined by the member's benefit program, eligibility on the date of service, and whether the services are medically necessary and appropriate; these policies are not a guarantee of coverage or payment.
- Final claim processing is based on the terms of the member's contract, including limitations and exclusions.
- Contact Capital Blue Cross Provider Services or Member Services with questions about a member's coverage.
Policy history and administrative notes — consensus reviews and administrative update
Administrative and consensus-review history: multiple consensus reviews between 2020 and 2025 reported no change to the policy statement; an administrative update on 07/23/2025 removed the Benefit Variations section and updated the disclaimer.
- 11/02/2020 — Consensus Review: No change to policy statement; references updated.
- 03/31/2021, 04/25/2022, 06/20/2023, 04/29/2024, 04/21/2025 — Consensus Reviews: No change to policy statement; coding reviewed with no coding changes and status/references updates as noted.
- 07/23/2025 — Administrative Update: Removed Benefit Variations section and updated Disclaimer.
Definitions and Terminology
Conservative Treatment Requirements Before PSFS
Policy History and Revision Notes
Removed Benefit Variations section and updated Disclaimer.
Regulatory status and references updated; coding reviewed with no coding changes.
No change to policy statement; regulatory information and references updated; coding reviewed with no coding changes.
No change to policy statement; references updated.
Updated cross references, FEP, and references; no changes to coding.
No change to policy statement; coding reviewed.
No change to policy statement; references updated.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.